Your browser is no longer supported. Please, upgrade your browser.
SEEL Seelos Therapeutics, Inc. daily Stock Chart
Seelos Therapeutics, Inc.
Index- P/E- EPS (ttm)-15.86 Insider Own53.60% Shs Outstand6.07M Perf Week-9.12%
Market Cap15.72M Forward P/E- EPS next Y- Insider Trans- Shs Float2.54M Perf Month5.71%
Income-10.00M PEG- EPS next Q- Inst Own41.42% Short Float15.09% Perf Quarter-60.76%
Sales- P/S- EPS this Y15.90% Inst Trans-12.47% Short Ratio0.12 Perf Half Y-69.17%
Book/sh5.19 P/B0.50 EPS next Y- ROA-154.20% Target Price1.50 Perf Year-87.84%
Cash/sh0.87 P/C2.97 EPS next 5Y- ROE-217.80% 52W Range1.32 - 21.45 Perf YTD-55.03%
Dividend- P/FCF- EPS past 5Y36.20% ROI- 52W High-87.93% Beta0.69
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low96.21% ATR0.69
Employees11 Current Ratio3.80 Sales Q/Q- Oper. Margin- RSI (14)43.00 Volatility16.63% 26.68%
OptionableNo Debt/Eq0.00 EPS Q/Q60.70% Profit Margin- Rel Volume11.18 Prev Close2.25
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.18M Price2.59
Recom3.00 SMA205.69% SMA50-36.25% SMA200-68.16% Volume35,557,537 Change15.11%
Mar-13-19 07:30AM  A Near Term FDA Clearance That Could Be The Beginning Of The Brain-Computer Revolution? ACCESSWIRE -14.29%
Mar-08-19 09:37AM  Shares of Seelos Therapeutics up 80% Friday morning MarketWatch +11.51%
09:35AM  Four Healthcare Stocks Looking To Close Out a Strong Week on Friday ACCESSWIRE
Mar-07-19 08:00AM  Seelos Therapeutics Announces Acquisition of an Exclusive License to Intellectual Property from The UC Regents to Potential Disease-Modifying Parkinson's Disease Therapy Created at UCLA GlobeNewswire +96.13%
Mar-06-19 02:45PM  Four Tech Stocks To Watch on Wednesday ACCESSWIRE
08:00AM  Seelos Therapeutics to Webcast Presentation at the 39th Annual Cowen Health Care Conference and Participate in the 31st Annual ROTH Conference GlobeNewswire
Mar-01-19 09:00AM  Seelos Therapeutics to Present at the 39th Annual Cowen Health Care Conference GlobeNewswire -13.51%
Feb-19-19 08:00AM  Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma GlobeNewswire -5.99%
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. The company was founded in 2016 and is based in New York, New York.